Building the Ecosystem to Change Care: From Ultrasensitive MRD to Clinical Impact
- Earlier Intervention in High Risk Populations: With >250,000 patients tested in 2025, Natera has established access to a previously under-characterized but clinically meaningful population—enabling development in earlier disease settings where relapse risk is high and therapeutic impact may be greatest
- The Integration of Sensitivity and Scale: With the integration of Foresight’s phased-variant technology into the Signatera™ platform, Natera combines ultrasensitive detection capabilities below 0.1ppm with an expansive commercial and operational infrastructure to support MRD-guided studies at scale
- De-risking MRD-guided Development: Natera’s ecosystem of trial-enablement tools, including site selection support, real-world insights, and commercial-to-trial enrollment pathways, enables more efficient, lower-risk development